Liver cancer screening method and device

Abstract

The invention discloses a liver cancer screening method and an application device, and the method comprises the following steps: (1) screening five liver cancer tumor marker combinations through a large number of experiments, namely alpha fetoprotein AFP, alpha fetoprotein variant AFP-L3, abnormal prothrombin DCP, Golgi protein GP73 and alpha-L-fucosidase AFU; (2) inputting the data of the five tumor markers into an ROC curve prediction model to obtain an area AUC value under an ROC curve; and (3) comparing the area AUC value with a preset threshold value, and determining the liver cancer risk levels to which the five tumor markers belong. Compared with the prior art, the kit can significantly improve the accuracy of liver cancer screening, and has the characteristics of high sensitivity and high accuracy.

Description

technical field [0001] The present invention relates to the field of internet technology of medical data, in particular to a liver cancer screening method and device. Background technique [0002] At present, primary hepatocellular carcinoma (hepatocellular carcinoma, HCC) is one of the most common malignant tumors in the world and the most common cause of death in patients with chronic liver disease. The five-year overall survival rate of liver cancer is currently only 14.1%. The morbidity and fatality rates are very close. The main reason for the low long-term survival rate of liver cancer is that the screening of high-risk groups of liver cancer is not popularized, and the early diagnosis rate is low, resulting in 70% to 80% of patients are already in the middle and late stage at the time of diagnosis. If early detection and early diagnosis can be implemented Radical methods such as liver resection and liver transplantation can significantly improve the prognosis of pati...

AI Technical Summary

Problems solved by technology

Golgi protein-73 (GP73) and α-L-fucosidase AFU are also markers of liver cancer, but their specificity and sensitivity are low, and false negatives or false positives are prone to occur

In addition, the method requires an experienced clinician to interpret the test results

[0006] Liver cancer screening in hospitals is to detect common tumor markers, the sensitivity and accuracy are low, and it is difficult to meet the requirements of early and rapid diagnosis

The conventional detection method is to detect the tumor marker AFP, but the specificity and sensitivity of AFP are low, and false negatives or false positives are prone to occur.

Images